Advanced Biomed sells Taiwan subsidiary for $490k; retains AI operations

Advanced Biomed Inc.

Sale of 100% of Taiwan subsidiary for $490k cash to buyer Miaozhu Zhao.
Taiwan subsidiary conducts biomedical R&D including A+PerfusC integrated perfusion 3D cell culture platform.
Company will continue AI-focused operations through Acellent Technologies (Hong Kong) Co. Limited.
Closing expected within three months from June 30, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.